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Abstract
Background: Cutaneous melanoma (CM) is the most lethal form of skin malignancy, which registers a constant
increase in incidence worldwide. The identification of molecular alteration(s) involved in its biological
aggressiveness represents a major challenge for researchers, considering that existing therapies are ineffective to
treat metastasizing cases. The epigenetic control of chromatin dynamics during DNA synthesis, replication, and
repair is fundamental for the orderly progression of cell proliferation. The Chromatin Assembly Factor 1 (CAF-1)
complex acts as a major regulator of this process; its intermediate (p60) subunit has been recently proposed as a
novel proliferation and prognostic marker for several tumors. We aimed to establish if the evaluation of the
expression of CAF-1/p60 in primary CM may help define the prevision of outcome of patients.
Methods: Immunohistochemistry with anti-CAF-1/p60 was performed on paraffin-embedded tissue sections of
130 cases of primary CM retrieved from the archive files of the Department of Biomorphological and Functional
Sciences, Section of Pathology, University “Federico II” of Naples, Italy. Results were compared with
histopathological and follow-up data of patients.
Results: CAF-1/p60 was expressed in all CM. A significant statistical association between the overexpression of the
protein and the occurrence of skin, node and/or distant metastases (P < 0.05) emerged, independently from
histopathological prognostic factors.
Conclusions: CAF-1/p60 looks promising as a new prognostic marker for CM and sheds new light on the
molecular events associated with photocancerogenesis and melanoma biology.
The screening for CAF-1/p60 might contribute to the molecular sub-classification of CM, with improved
translational outcomes.
Background
The incidence of cutaneous melanoma (CM) has shown
one of the higher increases of any form of cancer during
the past two generations [1]. Worldwide, about 100.000
new cases of CM are diagnosed each year and account for
more than 70% of all the deaths from skin tumors [1-5].
The increase in CM incidence is shared by Australia,
New Zealand, United States and most of European States,
notwithstanding the better knowledge of environmental
and phenotypic risk factors and ongoing primary and sec-
ondary prevention strategies [6-9]. To date, according to
the updated AJCC staging system, the most reliable pre-
dictors of patient outcome remain the extent of infiltra-
tion (Breslow thickness), the presence of ulceration and,
to a lesser extent, the tumor proliferation index [10]. The
estimated 10-year survival rates for non-metastatic CM
range from 93% for patients with “thin” tumors (</= 1.0
mm of dermal invasion, without ulceration and/or mitotic
index < 1/mm
2, Stage Ia), to 39% for patients with ulcer-
ated tumors deeper than 4.0 mm [10]. In about two-third
of progressing CM, loco-regional (skin and/or lymphatic)
metastatic spreading occurs, whereas in the remaining
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any medium, provided the original work is properly cited.cases, haematogenous metastases arise directly, at distant
anatomic sites [11].
Recent improvements in diagnostic techniques (i.e.:
epiluminescence dermoscopy) have led to diagnose most
CM at an early stage. However, the number of patients
that die for the disease remains still substantially
unchanged.
This disappointing result could be explained, at least
in part, by the heterogeneous nature of this malignancy
[5]. At present, it is thought that the aggressiveness of
melanoma may be conditioned by the variable concur-
rence of multiple factors, intrinsic to neoplastic cells (i.
e., imbalance of cell proliferation and apoptosis control
pathways), and/or micro-environmental (i.e., degree of
tumor neo-angiogenesis, expression of adhesion mole-
cules facilitating the migration of malignant cells) [12].
A sar e s u l t ,C Mm a yu l t i m a t e l ys h o wab i o l o g i c a l
behavior often unpredictable by means of the classical
histological prognostic parameters [10].
“Thin” melanomas can metastasize early, while some
“thick” t u m o r sm a ys h o wo n l yl a t em e t a s t a s i s( " d o r -
mant” melanoma) [13].
At present, except for high-dose IFN as adjuvant ther-
apy for stage III disease, effective strategies to treat
metastasizing melanomas are lacking; the median survi-
val of patients with distant metastases ranges from 6 to
10 months, with a 5-years survival lesser than 5% [14].
Therefore, the attention of the melanoma research com-
munity is devoted to the chance of translate significant
molecular studies results on melanoma biology into
clinical correlates and new therapeutic agents directed
at specific pathways.
Proteomic and genomic studies have revealed, in CM,
alterations of the expression of many oncogenes and
tumor suppressor genes responsible of either the DNA
damage repair and cell cycle control [15-19].
A fundamental role in the regulation of both these
processes has emerged for the molecular factors respon-
sible of the epigenetic regulation of nuclear chromatin
dynamics, that control also the packaging and interpre-
tation of the genome, in response to environmental sti-
muli [20-24].
Histone chaperones play a pivotal role in this process.
They drive the incorporation of different histones into
DNA to the sites where nuclear chromatin has to be
newly formed or remodeled [25].
Among these, the Chromatin Assembly Factor-1
(CAF-1), a trimeric protein complex formed by the p48,
p60, and p150 subunits, promotes histone incorporation
into chromatin and acts in strict association with both
the S-phase and DNA repair [26-29].
CAF-1 ensures the restoration of chromatin struc-
ture, providing that all aspects, including nucleosome
position and epigenetic imprints, are re-established
during the final step of DNA-repair, before cell-
replication.
Recently, CAF-1/p60 has been proposed as a new pro-
liferation and prognostic marker, since it has been
found over-expressed in a series of human malignancies,
in close association with their biological aggressiveness
[30-32].
Starting from these postulates, we sought to examine
the immunohistochemical expression of CAF-1/p60 on
a selected series of primary CM. These tumors notor-
iously look at UV-radiation as a major environmental
pathogenetic factor, and are characterized, in metastasi-
zing cases, by an extreme deregulation of cell prolifera-
tion and defects in DNA-repair. We have previously
evaluated the expression of the poly(ADP-ribose)poly-
merase 1 (PARP 1) in a series of melanomas of photo-
exposed skin areas [18]. As it is known, the family of
PARP proteins is directly involved in the epigenetic con-
trol of DNA-repair and cell death triggered by DNA
damage. We found a significative statistical correlation
between the inhibition of the PARP-1 mediated apopto-
sis and DNA repair process, and the metastasizing beha-
vior of CM [18]. In addition, we hypothesized that the
imbalance of PARP-1 activity could also be responsible,
at least in part, for the chemoresistence of metastatic
CM [18].
In the present study, considering the key role of CAF-
1 in the epigenetic regulation of either cell proliferation
and DNA-repair, we focused on the expression of CAF-
1/p60 on a series of 130 CM, among which were com-
prised the cases previously matched for poly(ADP-ribo-
syl)ation. The aim of the study was to verify the
hypothesis that the metastasizing behavior of CM could
be correlated with the alteration of more than a single
epigenetic pathway of DNA-repair and cell proliferation
control, and to establish the possible role of CAF-1/p60
as a new valuable predictor of prognosis for skin mela-
noma patients.
Methods
Study population
Formalin-fixed, paraffinized blocks of histologically con-
firmed primary CM were selected from the archive files
of the Department of Biomorphological and Functional
Sciences, Pathology Section, University Federico II of
Naples, among all the cases of skin melanomas surgi-
cally excised at the Dermatology Section and Plastic
Surgery of the Department of Systematic Pathology of
the same Institution between January 1985 and Decem-
ber 2007. Inclusion criteria were: (i) primary melanomas
that have arisen in photoexposed skin; (ii) absence of
multiple lesions, hereditary history of skin cancer, and/
or exposition to physical and/or chemical predisposing
factors; (iii) post-surgical clinical follow-up, covering a
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described selection criteria, 130 cases of primary CM
have been considered suitable for the study.
The study population consisted of 64 men and 66
women, with an average age of 47.02 years (range 17-84
years) (Table 1). The depth of vertical invasion (Breslow
thickness) of CM was lesser than 1.00 mm in 28 (21.6%)
cases, ranged from 1.01 and 2.00 mm in 51 cases
(39.2%), from 2.01 and 4.00 mm in 41 (31.5%), and was
deeper than 4.00 mm in 10 cases (7.7%) (Table 1). In all
cases, CM tissue derived from routine excision with
safety margins. Ulceration was found in 36 CM.
The follow-up was available for all patients (mean fol-
low-up: 9.01 years, range: 1-22 years).
Two patients (1.5%) developed skin (dermal/hypoder-
mal) metastasis during follow-up; 18 patients (13,8%)
had node metastasis, and 3 developed distant metastases
(2,3%); one patient (0,8%) experienced either nodal and
skin metastasis, and one patient (0,8%) developed skin
and distant metastases. Ten patients (7,7%) developed
both nodal and distant metastases. (Table 1)
Histopathological features and case histories have been
recorded in a standardized manner, and included age,
gender, tumor thickness (Breslow depth classes, accord-
ing to the American Joint Committee on Cancer, AJCC
2009), and the date of diagnosis [10].
The study was performed according to the guidelines
of the Institutional Ethic Committee, which, in agree-
ment with the Italian law, with reference to the topics
of the present research, do not provide for the Ethical
committee approval, and, according to the Declaration
of Helsinki require, for studies based on retrospective
analyses on routine archival formalin-fixed, paraffin
embedded tissue, only a written informed consent from
the alive patient, following the indication of Italian DLgs
n° 196/03 (Codex on Privacy) at the time of Surgery for
the primary melanoma.
Immunohistochemistry
For each case, 4-μm-thick serial sections have been cut
and mounted on poly-L-lysine coated glass slides. For
hyperpigmented tumors, bleaching of melanin was
achieved by incubating the sections in a solution of
0.25% potassium permanganate, 5% oxalic acid, for 60
minutes at room temperature. Paraffinized tissue blocks
of human normal skin from 10 patients that underwent
reconstructive surgery for non-neoplastic pathologies,
and 15 tissue blocks of benign melanocytic naevi (5
junctional, 5 compound and 5 intradermal) were used as
standard control for the expression of CAF-1/p60
respectively in normal melanocytes and in benign mela-
nocytic tumors.
Deparaffinized sections of all cases were boiled three
times for 3 min in a 10
-3 M sodium citrate buffer (pH
6.0) as antigen retrieval method. In order to prevent the
non-specific bindings of the antibody, the sections were
pre-incubated with non-immune mouse serum (1:20,
Dakopatts, Hamburg, Germany) diluted in PBS/BSA,
1%, for 25 minutes, at room temperature. After quench-
ing of endogenous peroxidases with 0.3% hydrogen per-
oxide in methanol, followed by two rinses with Tris-HCl
buffer, the sections were incubated, overnight at 4°C,
with the anti-CAF-1/p60 antibody (SS53 - ab8133,
Abcam, Cambridge, MA, USA, as previously described),
diluted 1:300 [30,31]. The standard streptavidin-biotin-
peroxidase complex technique was performed, using
sequential 20-minutes incubation with biotin-labeled
secondary antibody (1:30) and with peroxidase-labelled
streptavidin (1:30) for 10 minutes (DAKO LSAB kit
HRP, Carpinteria, CA). For the development of the per-
oxidase activity, 3, 3’-diaminobenzidine (DAB, Vector
Laboratories, Burlingame, U.S.A.) was used as a sub-
strate chromogen solution. Haematoxylin was used for
nuclear counterstaining, then the sections were mounted
and cover-slipped with a synthetic mounting medium
(Entellan, Merck, Germany). For each staining run were
used as positive controls sections from breast cancer
and oral squamous cell carcinoma [30,31]. Only cells
with a definite brown nuclear staining were judged posi-
tive for the antibody (Figure 1A, B). As previously
described, the immunohistochemical expression was
evaluated as percentage of positive tumour cells among
the total neoplastic cells present in at least 10 high
power fields. The expression of CAF-1/p60 was then
quantified semiquantitatively according to an arbitrary
scale, as follows: 0 (<10% of positive cells); + (10% - <
20%); ++ (20% - <30%); +++ (≥ 30% of positive cells)
[31,32]. Negative controls were performed substituting
Table 1 Clinical and pathological features of the study population of CM (ordered by Breslow depth, 130 total cases)
Breslow* Sex (M/F) Age (yrs) Ulceration Follow-up (yrs) Clinical outcome
≤/= 1.00 mm 16/12 (N° = 28) 46,1 (22-74) 2 11,3 (2-21) 1S; 1N
1.01 - 2.00 mm 24/27 (N° = 51) 47,6 (18-84) 9 9,1 (2-22) 1S; 4N; 1S, N; 1N, M; 1N, M, D
2.01-4.00 mm 19/22 (N° = 41) 45,8 (17-81) 16 7,6 (1-14) 10N; 3M; 2N, M; 4N, M, D
>4.00 mm 4/6 (N° = 10) 51,4 (30-81) 9 6.3 (1-23) 3N; 1N, M; 1S, M, D; 1N, M, D
* Breslow depth classes were determined according to AJCC system (2009)
10
S: skin (dermal/hypodermal) metastasis; N: nodal metastasis; M: distant metastasis; D: death for disease
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the same subclass, at the same concentration. Slides
were evaluated blindly by two observers (SS and MM)
and the cases with discordance were discussed and
resolved by consensus.
Statistical analysis
Data have been analyzed using the SPSS (version 13.0)
package for Windows and with software for Microsoft
Excel (a P-value of < 0.05). Univariate analysis of non-
parametric variables was performed by Spearman’sn o n -
parametric correlation test. Disease-free survival (DFS)
was calculated from the date of surgery for the primary
melanoma to the date of the occurrence of the first
loco-regional (dermal/hypodermal or nodal) and/or dis-
tant metastasis. Death was scored as an event, and alive
patients were censored at the time of the last follow-up.
DFS curves were drawn using Kaplan-Meier estimates
and were compared using log-rank test. Survival rates
were presented with their 95% confidence intervals.
Multinomial logistic regression was used to evaluate the
role of sex, age of patients, Breslow thickness, ulceration
and CAF-1/p60 expression in radial and vertical growth
phases of CM as predictor variables of unfavorable out-
come of the tumors
The prognostic accuracy of the selected predictor vari-
ables was tested by the receiver operating characteristics
(ROC) curve, in relation with the more significant prog-
nostic parameters. The area under the ROC curve has
been utilized to measure the discriminatory ability of
each parameter, as follows: < 0,7: no discrimination;
0,71-0,79: acceptable; 0,8-0,89: excellent; ≥ 0,9: outstand-
ing discrimination [33]
Results
Patients
As expected, DFS of patients was influenced by tumor
thickness. At the end of the follow-up, among the 35
cases of CM with an unfavorable follow-up, the Breslow
depth was < 1.0 mm in two cases (1.5%), comprised
between 1.01 and 2.00 mm in 8 cases (6.2%), between
2.01 and 4.00 mm in 19 cases (14.6%), and >4.00 mm in
6 CM (4.6%). Among these patients, 7 (20%) died (one
with cutaneous and distant metastases within 12 months
from the diagnosis, and six with nodal and distant
metastases, respectively after 7 and 60, 11 and 48, 8 and
44, 12 and 22, 5 and 12, 3 and 4 months from the diag-
nosis). (Table 1)
The percentage of cases with metastatic behavior
among each Breslow group of tumors varied as follows:
60% (6/10 patients) for CM deeper than 4.00 mm, 46.3%
(19/41 patients) for CM from 2.01 to 4.00 mm, 15.68%
(8/51 patients) for the melanomas between 1.01 and 2.0
mm, and 7.1% (2/28 patients) for CM thinner than 1.00
mm.
CAF-1 expression in normal melanocytes
In normal skin specimens, only a few melanocytes at the
dermal-epidermal junction showed low (+) nuclear
expression of CAF-1/p60.
CAF-1 expression in melanocytic naevi
Nuclear immunoreactivity for CAF-1/p60 was found in
up to 5% (low expression: +) of melanocytes, mainly
located at the junctional and superficial dermal levels.
Deep melanocytes showed, almost invariably, absence of
immunohistochemical expression of the protein.
CAF-1 expression in cutaneous melanoma
All the cases of CM showed nuclear expression of CAF-
1/p60 in cells of both the radial (intraepithelial) growth
phase and vertical (invasive) growth phase. The highest
Figure 1 Positive controls for CAF-1/p60 immunostaining.A
case of breast carcinoma (1A, ×400) and a case of squamous cell
carcinoma (1B, ×400) showing a strong expression of CAF-1/p60.
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in malignant melanocytes of the vertical growth phase
(in 37 cases); a moderate level of expression (++) was
found in 46 cases of vertical phase CM and in the radial
growth phase of 39 melanomas; a low expression level
(+) was found in the radial growth phase of the remain-
ing 91 CM (Figures 2, 3) (Table 2).
The cases of CM with the strongest CAF-1/p60
expression in vertical phase comprised all the 15 cases
in which previously an alteration of the poly-(ADP-ribo-
sil)ation process has been evidenced [18] (Table 2).
The univariate statistic analysis showed a correlation
between a moderate (++) level of CAF-1/p60 expression
in radial growth phase and a high (+++) expression of
the protein in the vertical growth phase of CM and sex
of patients.
A P < 0,001 level of significance resulted from the cor-
relation between a ++ expression of CAF-1/p60 in radial
growth phase, and a +++ expression in vertical growth
phase of CM and the Breslow depth, staging, recurrence
and/or death for disease (Tables 3,4). Table 5 shows the
detailed expression of CAF-1/p60 according to the Bre-
slow thickness.
Moreover, the analysis with log-rank testing showed
that the incidence of recurrence and death for disease of
patients was significantly associated (P = 0,001) with the
highest level (+++) of CAF-1/p60 expression in the ver-
tical phase of CM (Figure 4A, B)
The multivariate analysis (logistic regression analysis),
revealed that only high expression (+++) of CAF-1/p60
in vertical growth phase and staging had predictive sig-
nificance in respect to recurrence of melanomas (p <
0,0001 and p < 0,0001, respectively).
T h ep r o g n o s t i ca c c u r a c yo ft h e s et w op a r a m e t e r s
(CAF-1/p60 +++ hyperexpression in vertical growth
phase of CM and staging at the time of diagnosis) was
Figure 2 CAF-1 expression in “thin” cutaneous melanoma. A case of primary “thin” cutaneous melanoma (< 1 mm Breslow depth) showing
over-expression of CAF-1/p60. This patient experienced node metastasis 7 years from diagnosis (2A: original magnification, ×150; 2B: ×200);
“Thin” cutaneous melanoma, disease-free 11 years from surgery: low expression of CAF-1/p60; (2C: original magnification, ×200; 2D, ×250). Arrows
indicate the immunostained melanocytes.
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curve. In detail, patients were subdivided into 4 cate-
gories according to CAF-1/p60 expression (1: < 10%, 2:
11-20%, 3: 21-30%, 4: >30% positive cells) and into 8
categories according to staging sec. AJCC (stage groups:
0, IA, IB, IIA, IIB, IIC, III, IV).
Both parameters were able to accurately predict the
clinical outcome of CM patients even if the diagnostic
accuracy of CAF-1/p60 +++ expression level in the ver-
tical phase both was significantly better than that of sta-
ging (area under curve: 0,92 and 0.83, respectively,
Figure 5).
Both parameters were able to accurately predict
the clinical outcome of CM patients even if the diag-
nostic accuracy of CAF-1/p60 +++ expression level in
the vertical phase both was significantly better than
that of staging (area under curve: 0,92 and 0.83,
respectively).
Discussion
As it is known, despite its location within the protective
chromatin microenvironment, DNA is subject to
repeated damage by exogenous agents, such as ultravio-
let radiation (UV), which can impair replication and/or
transcription and must be corrected to prevent muta-
tions [24].
Chromatin dynamics tightly controls activation and
function of genes, by modulating the access of regula-
tory factors to DNA, and highly influences cellular beha-
vior of normal and neoplastic cells [21]. A highly
ordered coordination and organization of factors regu-
lating the opening and closing of chromatin is crucial to
ensure that the correct epigenetic code is maintained
within the genome [24].
Genomic instability is a major hallmark of tumor pro-
gression. It contributes to the gain of the invasive-meta-
static phenotype of neoplastic cells by favoring the
Figure 3 CAF-1 expression in thick cutaneous melanoma. Thick cutaneous melanoma (Breslow thickness: > 4 mm) with diffuse over-
expression of CAF-1/p60. This patient developed nodal and distant metastases and died for disease 2 years from diagnosis (3A: original
magnification, ×150; 3B, ×200); Thick cutaneous melanoma, disease-free 12 years after surgery: moderate expression of CAF-1/p60 (3C: original
magnification, ×150; 3D, ×200).
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ordered by Breslow depth
Case Age (y) Sex Breslow Ulceration Mitosis p60 r (%) p60 r p60 v (%) p60 v Follow-up (yrs)
1* 58 F ≤/= 1.00 no < 1 10 + 17 + 12
2* 36 M ≤/= 1.00 no ≥ 1 11 + 15 + 12
3* 67 M ≤/= 1.00 no < 1 10 + 18 + 12
4* 45 F ≤/= 1.00 no ≥ 1 10 + 13 + 12
5* 50 F ≤/= 1.00 no < 1 12 + 15 + 11
6* 49 F ≤/= 1.00 no ≥ 1 14 + 18 + 11
7* 42 M ≤/= 1.00 no < 1 10 + 14 + 10
8* 43 F ≤/= 1.00 no ≥ 11 2+1 4+ 9
9* 43 M ≤/= 1.00 no < 1 13 + 16 + 9
10* 49 M ≤/= 1.00 no ≥ 1 28 ++ 37 +++ 7
11* 40 M ≤/= 1.00 no ≥ 1 18 + 22 ++ 7
12* 41 M ≤/= 1.00 yes < 1 15 + 25 ++ 7
13* 39 M ≤/= 1.00 no < 1 27 ++ 45 +++ 6 S (52 m**)
14* 37 F ≤/= 1.00 no ≥ 1 17 + 28 ++ 6
15 42 M ≤/= 1.00 no < 1 12 + 16 + 14
16 37 M ≤/= 1.00 no < 1 13 + 19 + 19
17 67 M ≤/= 1.00 no ≥ 1 11 + 14 + 14
18 66 M ≤/= 1.00 no < 1 11 + 14 + 17
19 56 M ≤/= 1.00 no ≥ 1 10 + 23 ++ 2
20 35 M ≤/= 1.00 yes ≥ 1 15 + 20 ++ 7
21 32 F ≤/= 1.00 no < 1 14 + 22 ++ 6
22 73 M ≤/= 1.00 no ≥ 1 10 + 14 + 21
23 74 F ≤/= 1.00 no < 1 12 + 16 + 21
24 41 F ≤/= 1.00 no ≥ 1 10 + 14 + 14
25 48 F ≤/= 1.00 no < 1 11 + 15 + 14
26 22 M ≤/= 1.00 no ≥ 1 12 + 15 + 14
27 24 F ≤/= 1.00 no < 1 13 + 17 + 15
28 36 F ≤/= 1.00 no ≥ 1 28 ++ 50 +++ 4 N (7 m)
29* 66 F 1.01 - 2.00 no ≥ 1 26 ++ 70 +++ 12 N (8 m)
30* 65 F 1.01 - 2.00 no < 1 20 ++ 24 ++ 12
31* 56 M 1.01 - 2.00 yes ≥ 12 1 + +2 6+ + 1 2
32* 49 M 1.01 - 2.00 no < 1 12 + 14 + 12
33* 48 M 1.01 - 2.00 no ≥ 1 11 + 15 + 12
34* 39 F 1.01 - 2.00 no < 1 17 + 26 ++ 12
35* 47 F 1.01 - 2.00 yes ≥ 1 25 ++ 70 +++ 12 N (7 m), M(60 m), D(144 m)
36* 51 M 1.01 - 2.00 no < 1 10 + 22 ++ 11
37* 53 M 1.01 - 2.00 no ≥ 1 10 + 14 + 11
38* 56 M 1.01 - 2.00 no < 1 11 + 14 + 11
39* 51 F 1.01 - 2.00 no ≥ 1 18 + 21 ++ 10
40* 45 F 1.01 - 2.00 no < 1 10 + 15 + 10
41* 53 M 1.01 - 2.00 no ≥ 1 11 + 15 + 10
42* 67 M 1.01 - 2.00 no < 1 12 + 14 + 10
43* 54 M 1.01 - 2.00 no ≥ 1 10 + 15 + 10
44* 34 M 1.01 - 2.00 no ≥ 1 13 + 22 ++ 9
45* 44 F 1.01 - 2.00 no < 1 14 + 24 ++ 9
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Page 7 of 14Table 2: Clinical and pathological features and CAF-1/p60 immunohistochemical expression of 130 cases of CM
ordered by Breslow depth (Continued)
46* 43 F 1.01 - 2.00 no < 1 11 + 23 ++ 9
47* 71 F 1.01 - 2.00 no ≥ 1 10 + 23 ++ 9
48* 34 M 1.01 - 2.00 no < 1 15 + 20 ++ 9
49* 43 F 1.01 - 2.00 no ≥ 1 10 + 25 ++ 9
50* 51 F 1.01 - 2.00 no < 1 12 + 14 + 9
51* 50 M 1.01 - 2.00 no < 1 10 + 14 + 9
52* 39 F 1.01 - 2.00 no < 1 25 ++ 40 +++ 9 N (75 m)
53* 29 F 1.01 - 2.00 no ≥ 11 3+1 4+ 9
54* 42 M 1.01 - 2.00 no < 1 11 + 14 + 7
55* 37 F 1.01 - 2.00 yes ≥ 1 27 ++ 50 +++ 7 S (12 m), N(7 m)
56* 65 M 1.01 - 2.00 no < 1 10 + 14 + 7
57* 43 M 1.01 - 2.00 no ≥ 1 23 ++ 45 +++ 7 N(9 m)
58* 44 F 1.01 - 2.00 no < 1 10 + 28 ++ 6
59* 18 F 1.01 - 2.00 no ≥ 1 15 + 27 ++ 4
60* 22 M 1.01 - 2.00 no ≥ 1 14 + 25 ++ 4
61* 24 M 1.01 - 2.00 no < 1 12 + 22 ++ 4
62* 32 M 1.01 - 2.00 no < 1 10 + 23 ++ 4
63* 30 F 1.01 - 2.00 no < 1 12 + 21 ++ 4
64* 38 F 1.01 - 2.00 no ≥ 1 14 + 24 ++ 4
65* 37 M 1.01 - 2.00 no < 1 15 + 23 ++ 3
66* 40 M 1.01 - 2.00 no ≥ 1 10 + 22 ++ 3
67 51 M 1.01 - 2.00 no < 1 13 + 16 + 22
68 34 F 1.01 - 2.00 no ≥ 1 10 + 14 + 14
69 66 F 1.01 - 2.00 no < 1 12 + 14 + 15
70 60 M 1.01 - 2.00 yes < 1 11 + 14 + 13
71 48 F 1.01 - 2.00 no ≥ 1 10 + 14 + 14
72 28 M 1.01 - 2.00 yes < 1 24 ++ 58 +++ 2 N(3 m)
73 55 F 1.01 - 2.00 no ≥ 1 12 + 16 + 19
74 58 F 1.01 - 2.00 yes ≥ 1 28 ++ 50 +++ 4 S
75 32 F 1.01 - 2.00 no < 1 10 + 22 ++ 4
76 84 F 1.01 - 2.00 no ≥ 1 12 + 27 ++ 14
77 66 M 1.01 - 2.00 yes ≥ 1 26 ++ 47 +++ 14 N(5,6 m), M(9,25,32 m)
78 75 F 1.01 - 2.00 yes ≥ 1 12 + 14 + 14
79 64 F 1.01 - 2.00 no < 1 10 + 14 + 12
80* 40 M 2.01-4.00 no < 1 11 + 14 + 12
81* 36 M 2.01-4.00 no ≥ 1 14 + 14 + 12
82* 39 M 2.01-4.00 no < 1 10 + 22 ++ 11
83* 50 F 2.01-4.00 no ≥ 1 10 + 21 ++ 11
84* 48 F 2.01-4.00 no < 1 14 + 25 ++ 11
85* 45 M 2.01-4.00 yes ≥ 1 27 ++ 57 +++ 11 N(11 m), M(48 m), D(132 m)
86* 43 F 2.01-4.00 no ≥ 1 11 + 14 + 10
87* 53 F 2.01-4.00 no < 1 15 + 25 ++ 10
88* 47 M 2.01-4.00 no < 1 26 ++ 43 +++ 10 N(3 m)
89* 54 M 2.01-4.00 no ≥ 1 12 + 24 ++ 10
90* 50 M 2.01-4.00 no < 1 14 + 19 + 10
91* 69 F 2.01-4.00 no ≥ 1 12 + 14 + 10
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Page 8 of 14Table 2: Clinical and pathological features and CAF-1/p60 immunohistochemical expression of 130 cases of CM
ordered by Breslow depth (Continued)
92* 54 M 2.01-4.00 no < 1 10 + 14 + 10
93* 53 M 2.01-4.00 no < 1 10 + 22 ++ 9
94* 42 F 2.01-4.00 yes ≥ 1 25 ++ 68 +++ 9 N(8 m), M(44 m), D(108 m)
95* 37 F 2.01-4.00 yes ≥ 1 26 ++ 60 +++ 9 N(5 m), M(32 m)
96* 45 F 2.01-4.00 no < 1 12 + 14 + 9
97* 49 F 2.01-4.00 yes ≥ 1 27 ++ 59 +++ 9 N(12 m), M(22 m), D(108 m)
98* 32 M 2.01-4.00 yes ≥ 1 25 ++ 65 +++ 7 N(10 m)
99* 38 F 2.01-4.00 yes ≥ 1 28 ++ 68 +++ 6 N(10 m)
100* 38 M 2.01-4.00 no < 1 12 + 25 ++ 3
101* 32 M 2.01-4.00 yes ≥ 1 29 ++ 60 +++ 3 N(12 m), M(25 m)
102* 40 M 2.01-4.00 no < 1 13 + 23 ++ 3
103* 46 F 2.01-4.00 no ≥ 1 24 ++ 65 +++ 3 N(9 m)
104* 50 M 2.01-4.00 no < 1 12 + 24 ++ 2
105* 17 M 2.01-4.00 no < 1 22 ++ 55 +++ 12 N(84 m)
106* 30 M 2.01-4.00 no ≥ 1 15 + 25 ++ 2
107* 32 F 2.01-4.00 no < 1 20 ++ 36 +++ 2
108 81 F 2.01-4.00 yes ≥ 1 22 ++ 50 +++ 2 M(17 m)
109 56 F 2.01-4.00 no < 1 12 + 27 ++ 13
110 22 F 2.01-4.00 yes < 1 24 ++ 65 +++ 2 N(3 m)
111 21 M 2.01-4.00 yes < 1 14 + 22 ++ 14
112 60 F 2.01-4.00 no ≥ 1 25 ++ 60 +++ 1 N(4 m)
113 33 F 2.01-4.00 yes < 1 24 ++ 65 +++ 1 M(8 m)
114 60 M 2.01-4.00 no ≥ 1 15 + 23 ++ 13
115 73 F 2.01-4.00 yes < 1 22 ++ 70 +++ 12 N(12 m)
116 42 M 2.01-4.00 yes ≥ 1 26 ++ 68 +++ 6 N(6 m)
117 45 M 2.01-4.00 yes < 1 25 ++ 63 +++ 4 M(26,28 m)
118 56 F 2.01-4.00 no ≥ 1 24 ++ 70 +++ 13 N(5 m)
119 53 F 2.01-4.00 yes < 1 16 + 23 ++ 12
120 65 F 2.01-4.00 yes ≥ 1 26 ++ 65 +++ 2 N(5 m)M(12 m)D(24 m)
121 38 F >4.00 yes < 1 24 ++ 60 +++ 1 N(2 m)
122 55 F >4.00 yes < 1 17 + 21 ++ 14
123 56 F >4.00 yes < 1 23 ++ 68 +++ 11 N(3 m), M(24 m)
124 69 M >4.00 yes ≥ 1 18 + 22 ++ 6
125 81 F >4.00 yes < 1 24 ++ 58 +++ 1 N(12 m)
126 52 F >4.00 yes < 1 28 ++ 70 +++ 2 S(12 m), M(12 m), D(24 m)
127 30 F >4.00 yes ≥ 1 29 ++ 63 +++ 2 N(3 m), M(4 m), D(24 m)
128 54 M >4.00 no < 1 15 + 24 ++ 12
129 44 M >4.00 yes ≥ 1 27 ++ 70 +++ 12 N(3 m)
130 35 M >4.00 yes ≥ 1 12 + 25 ++ 2
S: skin (dermal/hypodermal) metastasis; N: nodal metastasis; M: distant metastasis; D: death for disease; °P60r: CAF-1/P60 in radial growth phase; °°P60v: CAF-1/
P60 in vertical growth phase; (*): cases previously matched for PARP-1 (poly-ADP-ribosyl)ase-1 expression; ** m = months.
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Page 9 of 14accumulation of sequential genetic and epigenetic
events. These latter include DNA methylation, histone
modifications, small, non-coding RNAs, and factors
involved in the regulation of chromatin architecture
[34-36].
Chromatin dynamics control nucleosome assembly
and higher order chromatin structure, and are responsi-
ble for the global nuclear organization and compartmen-
talization, tightly regulating gene expression and
controlling protein-DNA interactions within the cell
nucleus [37,38]. In particular, it allows the recognition
of DNA-damaged sequences and the segregation of the
damaged chromosomes, potential cause of genomic
Table 3 Clinic and pathologic findings in 130 patients with CM, according to CAF-1/p60 expression in radial and
vertical growth phase.
CLINICO-PATHOLOGIC FEATURES CAF-1/P60 radial growth phase CAF-1/P60 vertical growth phase
N° + % ++ % +++ % PVALUE° + % ++ % +++ % PVALUE°
AGE
≤30 13 9 69,2% 4 30,8% 0 0 NS 3 23,0% 6 46,2% 4 30,8% NS
>30 117 82 70,0% 35 30% 0 0 NS 44 37,6% 40 34,2% 33 28,2% NS
STAGING
IA 25 22 88,0% 3 12,0% 0 0 <0,001 19 76,0% 3 12,0% 3 12,0% <0,001
IB 45 42 93,3% 3 6,7% 0 0 <0,001 19 42,2% 24 53,3% 2 4,5% <0,001
IIA 28 20 71,4% 8 28,6% 0 0 <0,001 9 32,1% 12 42,8% 7 25,1% <0,001
IIB 16 3 18,7% 13 81,3% 0 0 <0,001 0 0 3 18,7% 13 81,3% <0,001
IIC 4 3 75,0% 1 25,0% 0 0 <0,001 0 0 1 25,0% 3 75,0% <0,001
IIIA 4 1 25,0% 3 75,0% 0 0 <0,001 0 0 1 25,0% 3 75,0% <0,001
IIIB 7 0 0 7 100% 0 0 <0,001 0 0 0 0 7 100% <0,001
IV 1 0 0 1 100% 0 0 <0,001 0 0 0 0 1 100% <0,001
BRESLOW
<1 mm 28 25 89,3% 3 10,7% 0 0 <0,001 19 67,8% 6 21,4% 3 10,8% <0,001
1.01-2.00 mm 51 41 80,4% 10 19,6% 0 0 <0,001 21 41,2% 22 43,1% 8 15,7% <0,001
2.01-4.00 mm 41 21 51,2% 20 48,8% 0 0 <0,001 7 17,1% 14 34,1% 20 48,8% <0,001
>4.00 mm 10 4 40,0% 6 60,0% 0 0 <0,001 0 0 4 40,0% 6 60,0% <0,001
PROGNOSIS
NO PROGRESSION 95 91 95,8% 4 4,2% 0 0 <0,001 47 49,5% 46 48,4% 2 2,1% <0,001
S/N/M* 35 0 0 35 100% 0 0 <0,001 0 0 0 0 35 100% <0,001
*S: skin (dermal/hypodermal) metastasis; N: nodal metastasis; M: distant metastasis; °(P value were calculated by t-test or ANOVA)
Table 4 Spearman’s correlation coefficient between all
variables analyzed.
Breslow P60r* P60v** Staging
Breslow/Correlation coefficient - ,369 ,386 ,909
Sig. (2-tailed) - ,000 ,000 ,000
Radial p60/Correlation coefficient ,369 - ,963 ,544
Sig. (2-tailed) ,000 - ,000 ,000
Vertical p60/Correlation coefficient ,386 ,963 - ,552
Sig. (2-tailed) ,000 ,000 - ,000
Staging/Correlation coefficient ,909 ,544 ,552 -
Sig. (2-tailed) ,000 ,000 ,000 -
*P60r: CAF-1/P60 in radial growth phase; **60v: CAF-1/P60 in vertical growth phase
Table 5 CAF-1/p60 expression in 130 primary melanomas subdivided according to Breslow thickness
Melanoma thickness Patients CAF-1/P60 radial growth phase CAF-1/P60 vertical growth phase
N° + % ++ % +++ % + % ++ % +++ %
≤ 1m m 28 25 19,2% 3 2,3% 0 0 19 14,6% 6 4,6% 3 2,3%
1.01-2 mm 51 41 31,6% 10 7,7% 0 0 21 16,1% 22 16,9% 8 6,2%
2.01-4 mm 41 21 16,1% 20 15,4% 0 0 7 5,4% 14 10,8% 20 15,4%
>4 mm 10 4 3,1% 6 4,6% 0 0 0 0 4 3,1% 6 4,6%
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Page 10 of 14instability, determining chromatin reshaping and war-
ranting the correct progression of the cell cycle and the
maintenance of genome integrity [39-41].
In melanomagenesis, the deregulation of cell prolifera-
tion results, at least in part, from the alteration of epige-
netic control checkpoints. In particular, the inactivation
of UV-specific pathways of DNA repair is a critical step.
In normal melanocytes, UV trigger histone acetylation
and the immediate activation of the histone poly-(ADP-
ribosyl)ation, a post-synthetic DNA epigenetic modifica-
tion which causes the generation of intracellular signals,
leading to the DNA repair or, in the case of excessive
damage, to apoptosis [24,41-43].
Recent data concerning the “chromatin ambient” of the
nucleus indicate a highly qualified role for chromatin
modifying proteins in the control of DNA replication and
DNA-repair [27,44,45]. The CAF-1 molecular complex
looks fundamental for the maintenance of the epigenetic
information; in particular, the deletion of CAF-1 subunits
in S. cerevisiae confers sensibility to UV radiation [24].
CAF-1, to date, is the only known chromatin assembly fac-
tor able to drive nucleosome assembly onto newly synthe-
sized DNA, and has a central role in ensuring chromatin
replication in S phase through the interaction with the
polymerase sliding clamp, PCNA [26,30,31,46-48]. It con-
stitutes the first example of a factor involved in chromatin
dynamics useful to assess cell proliferation [30]. The beha-
vior of its p60 and p150 subunits shares a number of simi-
larities with PCNA, which plays crucial roles in both DNA
replication and repair. Experimental data indicate that
Figure 4 Log-rank testing analysis. The incidence of recurrence (4A) and death for disease (4B) of patients is significantly associated with the
highest level (+++) of CAF-1/p60 expression in the vertical phase of CM (P = 0,001);
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Page 11 of 14particularly p60 is active in either the control of cell prolif-
eration and DNA-repair. Silencing of the p60 subunit by
RNAi leads to the accumulation of double-strand DNA
breaks and to the induction of programmed cell death in
proliferating but not quiescent human cells [49].
Recently, the involvement of CAF-1/p60 in neoplastic
progression has been reported, and its expression has
been proposed as a new tool to define the biological
behavior of some types of human malignancies (breast,
tongue, and prostate cancer) [30-32].
This opens up the possibility that its use could be
extended to malignancies of different histogenesis.
Here we show results supporting a role of CAF-1 in
predicting the aggressiveness of CM.
In our cases, the maximum level of over-expression of
CAF-1/p60 was found in the vertical growth phase of
CM characterized by a metastasizing behavior, besides
the Breslow thickness, ulceration and/or high mitotic
index. This suggests that CAF-1/p60 may shows a pro-
mising role as a relevant, adjunctive prognostic marker
for CM. Our results are in-line with previous data con-
cerning the alteration of the poly-(ADP-ribosil)ation
process in highly aggressive CM [18]. In particular, the
occurrence of CAF-1/p60 hyperexpression in the same
cases of CM previously found to bear an altered expres-
sion of PARP-1, indicates that the co-existence of the
deregulation of two of the major epigenetic pathways
responsible of DNA-repair and cell replication control,
constitutes a hallmark predictive of metastasizing beha-
vior in CM of photoexposed skin.
Investigations are being undertaken from our research
group to determine whether the alteration of such
mechanisms still retains with the same statistical signifi-
cance among a multi-institutional greater series of cases.
This perspective looks extremely attractive, because give
us means to built up a model in which the evaluation of
the CAF-1/p60 status of expression could get over the
limitations of current prognostic evaluation, particularly
for that concerning the “grey area” of CM with an inter-
mediate thickness (Breslow >1 and <2 mm).
In addition, it would be worth investigating how the
CAF-1 molecular pathway can be regulated, by modulat-
ing the expression of its subunits and their interactions
with the other histone chaperones and ATP-dependent
Figure 5 Receiver operating characteristic (ROC) curve. ROC curve evidence an excellent performance of CAF-1/p60 +++ expression level in
the vertical phase both in terms of sensitivity and specificity (area under curve: 0,92).
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Page 12 of 14chromatin remodelers. It has to be remembered, to this
regard, that in contrast to genetic alterations, epigenetic
modifications, although heritable in cells, are progres-
sive, quantitatively evaluable, potentially reversible, and
may serve as potential targets for drug treatment
[22,50,51]. Given the absence of effective therapy for
metastatic melanoma, the CAF-1 pathway may provide
a window of opportunity for novel post-surgical molecu-
lar therapies. Undoubtedly, future studies will provide
many exciting advances towards fully understanding of
the critical link between chromatin, DNA repair and cell
proliferation control, and the biology of CM.
Considering its essential role for cell cycle progression,
it might constitute a new therapeutic target with cyto-
static and/or cytotoxic effects that deserve to be investi-
gated in the future.
Basing on the results of the present study, however,
we believe that CAF-1/p60 expression is an exciting
chance to better predict the biological behavior of CM,
besides the traditional prognostic parameters.
Conclusions
This paper constitutes the first report of CAF-1/p60 up-
regulation in CM, and supports a noteworthy role for
CAF-1 in linking chromatin dynamics to the metastasiz-
ing behavior of this tumor.
Basing on results, CAF-1 looks like a promising candi-
date as a new prognostic marker which might give us
t h ec h a n c et oe a r l yd e t e c tt h es u b s e to fC Mp a t i e n t s
affected by metastasizing, hence deadly tumors, which
cannot be correctly detected on the basis of the existing
traditional parameters.
Many interesting questions remain still unanswered
about how chromatin remodeling influences replication,
transcription and repair within the tumorigenesis cascade
of CM. However, according to our opinion, our findings
have opened up new intriguing horizons that may enable
a better understanding of the biology of skin melanoma,
providing further insights into the contribution of the
epigenetic control of cell proliferation and DNA repair to
the gain of a metastasizing phenotype of CM.
Competing interests section
The authors declare that they have no competing
interests.
Acknowledgements
We thank Luana Argenio, BT and Emanuela Pone, BT for their assistance in
immunohistochemical staining of tissues; Alba Rocco, MD, PhD, for her
precious assistance for the statistical analysis of data and Amanda Tedeschi
for the editing of the English style of the manuscript.
Author details
1Department of Biomorphological and Functional Sciences, Pathology
Section, University of Naples “Federico II”, School of Medicine, Naples, Italy.
2Department of Systematic Pathology, Section of Dermatology, Allergology
and Venereology, University of Naples “Federico II”, School of Medicine,
Naples, Italy.
3Department of Systematic Pathology, Section of Plastic
Surgery, University of Naples “Federico II”, School of Medicine Naples, Italy.
4Department of Medicine, University of Naples “Federico II”, School of
Medicine, Naples, Italy.
5Cooperative Melanoma Intergroup, University of
Naples “Federico II”, School of Medicine, Naples, Italy.
6CROB, Oncology
Research Center of Basilicata, Rionero in Vulture, Potenza, Italy.
Authors’ contributions
MM participated in conception and design, analysis and interpretation of
data and drafting of manuscript. *MLV participated in analysis and
interpretation of data and acquisition and processing of images/
microphotographs. *GI carried out immunostaining of tissue section and
participated in analysis of data and drafting of the materials and methods
section. MS participated in collection of study population (skin biopsies and
sentinel node), acquisition of clinical data and clinical follow-up of patients.
GM participated in collection of study population (skin biopsies and sentinel
node), acquisition of clinical data and clinical follow-up of patients. MDB
participated in statistical analysis and interpretation of data. LN participated
in acquisition of data and drafting of the results section. *MS participated in
analysis and interpretation of data and acquisition and processing of
images/microphotographs. GDR participated in critical analysis of results and
manuscript revision. SS participated in conception and design, analysis and
interpretation of data, drafting and critical revision of the manuscript. All
authors read and approved the final manuscript.
Received: 6 August 2009 Accepted: 24 February 2010
Published: 24 February 2010
References
1. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A,
Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA,
Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET: Melanoma
Study Group of the Mayo Clinic Cancer Center. Malignant melanoma in
the 21st century, part 1: epidemiology, risk factors, screening,
prevention, and diagnosis. Mayo Clin Proc 2007, 82:364-80.
2. Garbe C, Leiter U: Melanoma epidemiology and trends. Clin Dermatol
2009, 27:3-9.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics,
2008. CA Cancer J Clin 2008, 58:71-96.
4. Larson AR, Konat E, Alani RM: Melanoma biomarkers: current status and
vision for the future. Nat Clin Pract Oncol 2009, 6:105-17.
5. Fecher LA, Cummings SD, Keefe MJ, Alani RM: Toward a molecular
classification of melanoma. J Clin Oncol 2007, 25:1606-20.
6. Wolff T, Tai E, Miller T: Screening for skin cancer: an update of the
evidence for the U.S. preventive service task force. Annals of internal
medicine 2009, 150:194-8.
7. Leiter U, Garbe C: Epidemiology of melanoma and non melanoma skin
cancer–the role of sunlight. Adv Exp Med Biol 2008, 624:89-103.
8. Reguiaï Z, Jovenin N, Bernard P, Derancourt C: Melanoma, past severe
sunburns and multiple solar lentigines of the upper back and shoulders.
Dermatology 2008, 216:330-6.
9. Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, Sagebiel RW, Guerry D,
Clark WH Jr: Clinically recognized dysplastic nevi. A central risk factor for
cutaneous melanoma. JAMA 1997, 277:1439-44.
10. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR,
Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT,
Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI,
Sober AJ, Sondak VK: Final version of 2009 AJCC Melanoma Staging and
Classification. J Clin Oncol 2009, 27:6199-206.
11. Leiter U, Meier F, Schittek B, Garbe C: The natural course of cutaneous
melanoma. J Surg Oncol 2004, 86:172-8.
12. Ruiter D, Bogenrieder T, Elder D, Herlyn M: Melanoma-stroma interactions:
structural and functional aspects. Lancet Oncol 2002, 3:35-43.
13. de Giorgi V, Massi D, Gerlini G, Mannone F, Quercioli E, Carli P: Immediate
local and regional recurrence after the excision of a polypoid
melanoma: tumor dormancy or tumor activation? Dermatol Surg 2003,
29:664-7.
14. Tsao H, Atkins MB, Sober AJ: Management of cutaneous melanoma. N
Engl J Med 2004, 351:998-1012.
Mascolo et al. BMC Cancer 2010, 10:63
http://www.biomedcentral.com/1471-2407/10/63
Page 13 of 1415. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of
the cyclin-dependent kinase-4 inhibitor gene in multiple human
cancers. Nature 1994, 368:753-6.
16. Staibano S, Lo Muzio L, Pannone G, Somma P, Farronato G, Franco R,
Bambini F, Serpico R, De Rosa G: P53 and hMSH2 expression in basal cell
carcinomas and malignant melanomas from photoexposed areas of
head and neck region. Int J Oncol 2001, 19:551-9.
17. Lo Muzio L, Nocini P, Mignogna MD, Pannone G, Staibano S, Procaccini M,
Rubini C, Fioroni M, Fanali S, Piattelli A: Immunocytochemical detection of
hMSH2 and hMLH1 expression in oral melanoma. Anticancer Res 2000,
20:741-8.
18. Staibano S, Pepe S, Lo Muzio L, Somma P, Mascolo M, Argenziano G,
Scalvenzi M, Salvatore G, Fabbrocini G, Molea G, Bianco AR, Carlomagno C,
De Rosa G: PARP-1 expression in malignant melanomas from
photoexposed areas of the head and neck region. Hum Pathol 2005,
36:724-31.
19. Boisvert-Adamo K, Longmate W, Abel EV, Aplin AE: Mcl-1 is required for
melanoma cell resistance to anoikis. Mol Cancer Res 2009, 7:549-56.
20. Jones PA, Baylin SB: The epigenomics of cancer. Cell 2007, 128:683-92.
21. Kouzarides T: Chromatin modifications and their function. Cell 2007,
128:693-705.
22. Ozanne SE, Constância M: Mechanisms of disease: the developmental
origins of disease and the role of the epigenotype. Nat Clin Pract
Endocrinol Metab 2007, 3:539-46.
23. Liu S, Ren S, Howell P, Fodstad O, Riker AI: Identification of novel
epigenetically modified genes in human melanoma via promoter
methylation gene profiling. Pigment Cell Melanoma Res 2008, 21:545-58.
24. Ehrenhofer-Murray AE: Chromatin dynamics at DNA replication,
transcription and repair. Eur J Biochem 2004, 271:2335-49.
25. Ramirez-Parra E, Gutierrez C: The many faces of chromatin assembly
factor 1. Trends Plant Sci 2007, 12:570-6.
26. Tagami H, Ray-Gallet D, Almouzni G, Nakatami Y: H3.1 and H3.3 complexes
mediate nucleosome assembly pathways dependent or independent of
DNA synthesis. Cell 2004, 116:51-61.
27. Linger JG, Tyler JK: Chromatin disassembly and reassembly during DNA
repair. Mutat Res 2007, 618:52-64.
28. Gaillard PH, Martini EM, Kaufman PD, Stillman B, Moustacchi E, Almouzni G:
Chromatin assembly coupled to DNA repair: a new role for chromatin
assembly factor I. Cell 1996, 86:887-96.
29. Verger A, Crossley M: Chromatin modifiers in transcription and DNA
repair. Cell Mol Life Sci 2004, 61:2154-62.
30. Polo SE, Yheocharis SE, Klijaieko J, Savignoni A, Asselain B, Almouzni G:
CAF-1, a marker of clinical value to distinguish quiescent from
proliferative cells. Cancer Res 2004, 64:2371-81.
31. Staibano S, Mignogna C, Lo Muzio L, Mascolo M, Salvatore G, Di
Benedetto M, Califano L, Rubini C, De Rosa G: Chromatin Assembly Factor-
1 (CAF-1)-mediated regulation of cell proliferation repair: a link with the
biological behaviour of squamous cell carcinoma of the tongue.
Histopathology 2007, 50:911-9.
32. Staibano S, Mascolo M, Mancini FP, Kisslinger A, Salvatore G, Di
Benedetto M, Chieffi P, Altieri V, Prezioso D, Ilardi G, De Rosa G,
Tramontano D: Overexpression of chromatin assembly factor-1 (CAF-1)
p60 is predictive of adverse behaviour of prostatic cancer. Histopathology
2009, 54:580-9.
33. Zweigh MH, Campbell G: Receiver operating characteristic (ROC) plats: a
fundamental evaluation tool in clinical medicine. Clin Chem 1993,
39:561-77.
34. ENCODE Project Consortium, Birney E, Stamatoyannopoulos JA, Dutta A,
et al: Identification and analysis of functional elements in 1% of the
human genome by the ENCODE pilot project. Nature 2007, 447:799-816.
35. Li B, Carey M, Workman JL: The role of chromatin during transcription.
Cell 2007, 128:707-19.
36. Ruthenburg AJ, Li H, Patel DJ, Allis CD: Multivalent engagement of
chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol
2007, 8:983-94.
37. Fog CK, Jensen KT, Lund AH: Chromatin-modifying proteins in cancer.
APMIS 2007, 115:1060-89.
38. Ridgway P, Almouzni G: Chromatin assembly and organization. J Cell Sci
2001, 114:2711-2.
39. Hoek M, Stillman B: CAF-1 is essential and couplet chromatin assembly
t DNA replication in vivo. Proc Natl Acad SCI USA 2003, 100:12183-8.
40. Ridgway P, Almouzni G: CAF-1 and the inheritance of chromatin states: at
the crossroads of DNA replication and repair. J Cell Sci 2000, 113:2647-58.
41. Vodenicharov MD, Ghodgaonkar MM, Halappanavar SS, Shah RG, Shah GM:
Mechanism of early biphasic activation of poly(ADP-ribose) polymerase-
1 in response to ultraviolet B radiation. J Cell Sci 2005, 118:589-99.
42. Bossi O, Gartsbein M, Leitges M, Kuroki T, Grossman S, Tennenbaum T: UV
irradiation increases ROS production via PKCdelta signaling in primary
murine fibroblasts. J Cell Biochem 2008, 105:194-207.
43. Zhu Q, Wani G, Arab HH, El-Mahdy MA, Ray A, Wani AA: Chromatin
restoration following nucleotide excision repair involves the
incorporation of ubiquitinated H2A at damaged genomic sites. DNA
Repair 2009, 8:262-73.
44. Henikoff S: Versatile assembler. Nature 2003, 423:814-7.
45. Polo S, Almouzni G: Chromatin assembly: a basic recipe with various
flavours. Curr Opin Genet Dev 2006, 16:104-111.
46. Shibahara K, Stillman B: Replication-dependent marking of DNA by PCNA
facilitates CAF-1 coupled inheritance of chromatin. Cell 1999, 96:575-85.
47. Krawitz DC, Kama T, Kaufman PD: Chromatin assembly factor I mutants
defective for PCNA binding require Asf1/Hir proteins for silencing. Mol
Cell Biol 2002, 22:614-25.
48. Martini E, Roche DM, Maherineke K, Verreault A, Almouzni G: Recruitment
of phosphorylated chromatin assembly factor 1 after UV irradiation of
Human cells. J Cell Biol 1998, 143:563-75.
49. Nabatiyan A, Krude T: Silencing of chromatin assembly factor 1 in human
cells leads to cell death and loss of chromatin assembly during DNA
synthesis. Mol Cell Biol 2004, 24:2853-62.
50. Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, Zhang X,
Bernstein BE, Nusbaum C, Jaffe DB, Gnirke A, Jaenisch R, Lander ES:
Genome-scale DNA methylation maps of pluripotent and differentiated
cells. Nature 2008, 454:766-70.
51. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G,
Chepelev I, Zhao K: High-resolution profiling of histone methylations in
the human genome. Cell 2007, 129:823-37.
Pre-publication history
The pre-publication history for this paper can be accessed here:http://www.
biomedcentral.com/1471-2407/10/63/prepub
doi:10.1186/1471-2407-10-63
Cite this article as: Mascolo et al.: Overexpression of Chromatin
Assembly Factor-1/p60 helps to predict the prognosis of melanoma
patients. BMC Cancer 2010 10:63.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mascolo et al. BMC Cancer 2010, 10:63
http://www.biomedcentral.com/1471-2407/10/63
Page 14 of 14